Heteroaryl dihydroindolones as kinase inhibitors
US8455535B2 · kind B2 · utility
3Cited by
15References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2011 |
| Grant date | Jun 4, 2013 |
| Priority date | — |
| Expiry date | Jun 1, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound represented by the formula:wherein ring systems A and B, and the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. The compounds of the present invention may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, such as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.